Cadila Healthcare Limited has informed the Exchange about press release dated 08-Mar-2022 titled Sentynl Therapeutics Inc., a wholly owned subsidiary of Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) and BridgeBio Pharma Announce Asset Purchase Agreement for BridgeBio Pharma���s
Press Release Mar 08 2022
Filed with NSE · · 5 pages · English
Summary by 6ix AI
The agreement allows Zydus's subsidiary, Sentynl Therapeutics, to acquire global rights to NULIBRY and manage its development and commercialization. This acquisition aims to address unmet healthcare needs for children with molybdenum cofactor deficiency, a life-threatening condition. The press release emphasizes Zydus's commitment to empowering patients with rare diseases through innovative therapies.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 07 2022
- Press Release Feb 23 2022
- Press Release Feb 14 2022
- Press Release Feb 02 2022
- Press Release Jan 20 2022
Later from Zydus Lifesciences
- Press Release Mar 09 2022
- Press Release Mar 14 2022
- Press Release Mar 21 2022
- Press Release Apr 01 2022
- Press Release Apr 13 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences